Clinical Trial Update: A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies [Phase 1]

View source ↗

Summary

This phase 1 dose-escalation study evaluated MEDI-551 (inebilizumab) in Japanese adults with relapsed or refractory advanced B-cell malignancies, focusing on sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Blood Cancer, Advanced B Cell Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2017-04-10